The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice
Abstract
Mutations in dystrophin cause Duchenne muscular dystrophy (DMD), but absent dystrophin does not invariably cause necrosis in all muscles, life stages and species. Using DNA microarray, we established a molecular signature of dystrophinopathy in the mdx mouse, with evidence that secondary mechanisms are key contributors to pathogenesis. We used variability controls, adequate replicates and stringent analytic tools, including significance analysis of microarrays to estimate and manage false positive rates. In leg muscle, we identified 242 differentially expressed genes, >75% of which have not been previously reported as altered in human or animal dystrophies. Data provide evidence for coordinated activity of numerous components of a chronic inflammatory response, including cytokine and chemokine signaling, leukocyte adhesion and diapedesis, invasive cell type-specific markers, and complement system activation. Selective chemokine upregulation was confirmed by RT-PCR and immunoblot, and may be a key determinant of the nature of the inflammatory response in dystrophic muscle. Up-regulation of secreted phosphoprotein 1 (minopontin, osteopontin) mRNA and protein in dystrophic muscle identified a novel linkage between inflammatory cells and repair processes. Extracellular matrix genes were up-regulated in mdx to levels similar to those in DMD. Since, unlike DMD, mdx exhibits little fibrosis, data suggest that collagen regulation at post-transcriptional stages mediates extensive fibrosis in DMD. Taken together, these data identify a relatively neglected aspect of DMD, suggest new treatment avenues, and highlight the value of genome-wide profiling in study of complex disease processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaughter, C. A., Sernett, S. W., & Campbell, K. P. (1992) · Nature · doi:10.1038/355696a0 · Cited by 1,410
Eta-1 (Osteopontin): An Early Component of Type-1 (Cell-Mediated) Immunity
Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S., Rittling, S. R., Denhardt, D. T., Glimcher, M. J., & Cantor, H. (2000) · Science · doi:10.1126/science.287.5454.860 · Cited by 1,125
Altered wound healing in mice lacking a functional osteopontin gene (spp1).
Liaw, L., Birk, D. E., Ballas, C. B., Whitsitt, J. S., Davidson, J. M., & Hogan, B. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2131 · Cited by 663
Expression Profiling in the Muscular Dystrophies
Chen, Y.-W., Zhao, P., Borup, R., & Hoffman, E. P. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.6.1321 · Cited by 478
Sander, M., Chavoshan, B., Harris, S. A., Iannaccone, S. T., Stull, J. T., Thomas, G. D., & Victor, R. G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250379497 · Cited by 445
Agnihotri, R., Crawford, H. C., Haro, H., Matrisian, L. M., Havrda, M. C., & Liaw, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103608200 · Cited by 414
Disruption of the Sarcoglycan–Sarcospan Complex in Vascular Smooth Muscle
Coral-Vazquez, R., Cohn, R. D., Moore, S. A., Hill, J. A., Weiss, R. M., Davisson, R. L., Straub, V., Barresi, R., Bansal, D., Hrstka, R. F., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81975-3 · Cited by 371
Emslie-Smith, A. M., Arahata, K., & Engel, A. G. (1989) · Human Pathology · doi:10.1016/0046-8177(89)90128-7 · Cited by 349
Cited by
Nuclear factor-?B: its role in health and disease
Kumar, A., Takada, Y., Boriek, A., & Aggarwal, B. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0555-y · Cited by 933
Aberrant repair and fibrosis development in skeletal muscle
Mann, C. J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A. L., & Muñoz-Cánoves, P. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-21 · Cited by 853
“However, in chronic human diseases such as DMD and many other dystrophies, newly generated fibers are also prone to degeneration because they retain the underlying molecular defect, producing constant cycles of fiber degeneration associated with chronic inflammation (Figure 1) [4].”
BackgroundLemos, D. R., Babaeijandaghi, F., Low, M., Chang, C.-K., Lee, S. T., Fiore, D., Zhang, R.-H., Natarajan, A., Nedospasov, S. A., & Rossi, F. M. V. (2015) · Nature Medicine · doi:10.1038/nm.3869 · Cited by 740
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A., Kuntzer, T., Pike, M., & Swan, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub2 · Cited by 539
The Dystrophin Glycoprotein Complex: Signaling Strength and Integrity for the Sarcolemma
Lapidos, K. A., Kakkar, R., & McNally, E. M. (2004) · Circulation Research · doi:10.1161/01.res.0000126574.61061.25 · Cited by 524
Corticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493
Solchaga, L. A., Penick, K., Porter, J. D., Goldberg, V. M., Caplan, A. I., & Welter, J. F. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20238 · Cited by 479
Self-citationAcharyya, S., Villalta, S. A., Bakkar, N., Bupha-Intr, T., Janssen, P. M. L., Carathers, M., Li, Z.-W., Beg, A. A., Ghosh, S., Sahenk, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30556 · Cited by 438
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A. Y., Kuntzer, T., Pike, M., & Swan, A. V. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub3 · Cited by 437
Cellular dynamics in the muscle satellite cell niche
Bentzinger, C. F., Wang, Y. X., Dumont, N. A., & Rudnicki, M. A. (2013) · The EMBO Reports · doi:10.1038/embor.2013.182 · Cited by 398
“Unlike the beneficial effects of transient ECM protein upregulation during normal regeneration, increased inflammation and persistent expression of ECM proteins reduce the differentiation of myoblasts into myo-fibres [98,99].”
Haslett, J. N., Sanoudou, D., Kho, A. T., Bennett, R. R., Greenberg, S. A., Kohane, I. S., Beggs, A. H., & Kunkel, L. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192571199 · Cited by 364
Mechanisms of Muscle Degeneration, Regeneration, and Repair in the Muscular Dystrophies
Wallace, G. Q., & McNally, E. M. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163216 · Cited by 342
Vetrone, S. A., Montecino-Rodriguez, E., Kudryashova, E., Kramerova, I., Hoffman, E. P., Liu, S. D., Miceli, M. C., & Spencer, M. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37662 · Cited by 279
Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy
Chen, Y. W., Nagaraju, K., Bakay, M., McIntyre, O., Rawat, R., Shi, R., & Hoffman, E. P. (2005) · Neurology · doi:10.1212/01.wnl.0000173836.09176.c4 · Cited by 276
Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration
Goetsch, S. C., Hawke, T. J., Gallardo, T. D., Richardson, J. A., & Garry, D. J. (2003) · Physiological Genomics · doi:10.1152/physiolgenomics.00056.2003 · Cited by 275
Regulation of the muscle fiber micro environment by activated satellite cells during hypertrophy
Fry, C. S., Lee, J. D., Jackson, J. R., Kirby, T. J., Stasko, S. A., Liu, H., Dupont‐Versteegden, E. E., McCarthy, J. J., & Peterson, C. A. (2014) · The FASEB Journal · doi:10.1096/fj.13-239426 · Cited by 273
IGF-1, inflammation and stem cells: interactions during muscle regeneration
MOURKIOTI, F., & ROSENTHAL, N. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.002 · Cited by 272
Pelosi, L., Giacinti, C., Nardis, C., Borsellino, G., Rizzuto, E., Nicoletti, C., Wannenes, F., Battistini, L., Rosenthal, N., Molinaro, M., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7690com · Cited by 268
Hsp72 preserves muscle function and slows progression of severe muscular dystrophy
Gehrig, S. M., van der Poel, C., Sayer, T. A., Schertzer, J. D., Henstridge, D. C., Church, J. E., Lamon, S., Russell, A. P., Davies, K. E., Febbraio, M. A., et al. (2012) · Nature · doi:10.1038/nature10980 · Cited by 250
Cellular and Molecular Mechanisms Regulating Fibrosis in Skeletal Muscle Repair and Disease
Serrano, A. L., Mann, C. J., Vidal, B., Ardite, E., Perdiguero, E., & Muñoz-Cánoves, P. (2011) · Current Topics in Developmental Biology · doi:10.1016/b978-0-12-385940-2.00007-3 · Cited by 200
Hall, T. E., Bryson-Richardson, R. J., Berger, S., Jacoby, A. S., Cole, N. J., Hollway, G. E., Berger, J., & Currie, P. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700942104 · Cited by 178
Villalta, S. A., Deng, B., Rinaldi, C., Wehling-Henricks, M., & Tidball, J. G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101267 · Cited by 158
“candidate cytokine for promoting M1 activation in mdx muscle because it has the capacity to promote M1 activation and cytotoxicity (29) and its expression is elevated in mdx muscle (30), our current findings do not support that role for TNF-a in mdx dystrophy.”
BackgroundRegulation of muscle atrophy in aging and disease
Vinciguerra, M., Musaro, A., & Rosenthal, N. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7002-2_15 · Cited by 149
Thalacker-Mercer, A., Stec, M., Cui, X., Cross, J., Windham, S., & Bamman, M. (2013) · Physiological Genomics · doi:10.1152/physiolgenomics.00167.2012 · Cited by 119
Age dependent increase in the levels of osteopontin inhibits skeletal muscle regeneration
Paliwal, P., Pishesha, N., Wijaya, D., & Conboy, I. M. (2012) · Aging · doi:10.18632/aging.100477 · Cited by 89
Involvement of adiponectin in the pathogenesis of dystrophinopathy
Abou-Samra, M., Lecompte, S., Schakman, O., Noel, L., Many, M. C., Gailly, P., & Brichard, S. M. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0051-9 · Cited by 55
AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
Abou‐Samra, M., Selvais, C. M., Boursereau, R., Lecompte, S., Noel, L., & Brichard, S. M. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12531 · Cited by 44
“To this end, AdipoRon was orally administered for a period of 2 months, very early in mdx mice because muscle degenerative-regenerative cycles begin as soon as 3–4 weeks of age.(17,18) We first examined whether treated mdx mice exhibited lower degree of skeletal muscle inflammation, oxidative stress, and injury togeth…”
BackgroundPotential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy
Abou-Samra, M., Boursereau, R., Lecompte, S., Noel, L., & Brichard, S. M. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.02.018 · Cited by 24
Apolinário, L. M., De Carvalho, S. C., Santo Neto, H., & Marques, M. J. (2015) · The Anatomical Record · doi:10.1002/ar.23177 · Cited by 22
Metadata
- Authors
- Porter, J. D.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-02-01
- Volume
- 11
- Issue
- 3
- Pages
- 263-272
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2166059867
- Cited by
- 442
- References
- 47
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.